Mitochondrial tumour suppressors: A genetic and biochemical update

Nature Reviews Cancer

Volumn 5, Issue 11, 2005, Pages 857-866

  Gottlieb, Eyal ^a   Tomlinson, Ian P M ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOCHONDRIAL PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER; CANCER INHIBITION; CITRIC ACID CYCLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME SUBUNIT; FUMARATE HYDRATASE GENE; GENE EXPRESSION; GENE MUTATION; GENOME IMPRINTING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LEIOMYOMA; LEIOMYOSARCOMA; MITOCHONDRIAL RESPIRATION; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY CHAIN; REVIEW; SDHB GENE; SDHC GENE; SDHD GENE; SIGNAL TRANSDUCTION;

ANIMALS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 28544446058     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1737     Document Type: Review

References (98)

1. Warburg, O., Wind, F. & Neglers, E. in Metabolism of Tumours (ed. Warburg, O.) 254-270 (Constable & Co., London, 1930).
2. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
3. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
4. Carew, J. S. & Huang, P. Mitochondrial defects in cancer. Mol. Cancer 1, 9 (2002).
5. Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291-293 (1998). This work showed for the first time that the majority of colorectal cancer cells contain somatic and mostly homoplasmic mutations in their mtDNA.
6. Coller, H. A. et al. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nature Genet. 28, 147-150 (2001).
7. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA 102, 719-724 (2005).
8. Shidara, Y. et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res. 65, 1655-1663 (2005).
9. Yankovskaya, V. et al. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299, 700-704 (2003). A comprehensive study of the E. coli SDH homologue structure and function. Based on the electron distribution in redox centres, this work makes important analogies to the structure and function of human SDH, and discusses the potential role of several SDH mutations in ROS generation.
10. Astuti, D. et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49-54 (2001).
11. Baysal, B. E. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848-851 (2000). The first discovery of a mitochondrial tumour-suppressor gene in HPGL.
12. Niemann, S. & Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genet. 26, 268-270 (2000).
13. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet. 30, 406-410 (2002). References 10-13 were the first studies to characterize SDHB, SDHD, SDHC and FH as tumour suppressors in the hereditary syndromes PGL4, PGL1, PGL3 and HLRCC, respectively.
14. Launonen, V. et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98, 3387-3392 (2001).
15. Baysal, B. E. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol. Metab. 14, 453-459 (2003).
16. Eng, C., Kiuru, M., Fernandez, M. J. & Aaltonen, L. A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Rev. Cancer 3, 193-202 (2003).
17. Pollard, P. J., Wortham, N. C. & Tomlinson, I. P. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann. Med. 35, 632-639 (2003).
18. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85 (2005). This work described the metabolic signalling mechanism showing that succinate can behave as an intracellular messenger that links SDH dysfunction to HIF induction.
19. Holme, E. et al. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A→G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am. J. Hum. Genet. 52, 551-556 (1993).
20. Gimm, O., Armanios, M., Dziema, H., Neumann, H. P. & Eng, C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res. 60, 6822-6825 (2000).
21. Favier, J. et al. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm. Res. 63, 171-179 (2005).
22. Tomitsuka, E., Goto, Y., Taniwaki, M. & Kita, K. Direct evidence for expression of type II flavoprotein subunit in human complex II (succinate-ubiquinone reductase). Biochem. Biophys. Res. Commun. 311, 774-779 (2003).
23. Tomitsuka, E. et al. Direct evidence for two distinct forms of the flavoprotein subunit of human mitochondrial complex II (succinate-ubiquinone reductase). J. Biochem. (Tokyo) 134, 191-195 (2003).
24. Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet 12, 1241-1252 (2003).
25. Taschner, P. E. et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer 31, 274-281 (2001).
26. Niemann, S., Muller, U., Engelhardt, D. & Lohse, P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum. Genet. 113, 92-94 (2003).
27. McWhinney, S. R. et al. Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J. Clin. Endocrinol. Metab. 89, 5694-5699 (2004).
28. Baysal, B. E. et al. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. J. Med. Genet. 41, 703-709 (2004).
29. Chan, I., Wong, T., Martinez-Mir, A., Christiano, A. M. & McGrath, J. A. Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer. Clin. Exp. Dermatol. 30, 75-78 (2005).
30. Toro, J. R. et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95-106 (2003).
31. Douwes Dekker, P. B. et al. SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. J. Pathol. 201, 480-486 (2003).
32. Neumann, H. P. et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292, 943-951 (2004).
33. Gimenez-Roqueplo, A. P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63, 5615-5621 (2003).
34. Maier-Woelfle, M. et al. A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas. J. Clin. Endocrinol. Metab. 89, 362-367 (2004).
35. Rustin, P., Munnich, A. & Rotig, A. Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur. J. Hum. Genet. 10, 289-291 (2002).
36. Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153-159 (2004).
37. Astuti, D. et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 357, 1181-1182 (2001).
38. Baysal, B. E. et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 39, 178-183 (2002).
39. Neumann, H. P. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459-1466 (2002).
40. Benn, D. E. et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22, 1358-1364 (2003).
41. Dannenberg, H. et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J. Clin. Oncol. 23, 1894-1901 (2005).
42. Mhatre, A. N., Li, Y., Feng, L., Gasperin, A. & Lalwani, A. K. SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas. Clin. Genet. 66, 461-466 (2004).
43. Dannenberg, H. et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin. Cancer Res. 8, 2061-2066 (2002).
44. Masuoka, J. et al. Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene 20, 5084-5086 (2001).
45. Barker, K. T. et al. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br. J. Cancer 87, 446-448 (2002).
46. Kiuru, M. et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62, 4554-4557 (2002).
47. Pollard, P. et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J. Pathol. 205, 41-49 (2005). Shows a phenotypic link between FH mutations and pseudo-hypoxia.
48. Lehtonen, R. et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am. J. Pathol. 164, 17-22 (2004).
49. Kiuru, M. et al. No germline FH mutations in familial breast cancer patients. Eur. J. Hum. Genet. 13, 506-509 (2005).
50. Morris, M. R. et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J. Clin. Pathol. 57, 706-711 (2004).
51. Newmeyer, D. D. & Ferguson-Miller, S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112, 481-490 (2003).
52. Karbowski, M. & Youle, R. J. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 10, 870-880 (2003).
53. Downward, J. Cell biology: metabolism meets death. Nature 424, 896-897 (2003).
54. Ricci, J. E. et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 117, 773-786 (2004).
55. Albayrak, T. et al. The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. Mol. Biol. Cell 14, 3082-3096 (2003).
56. Ishii, T. et al. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 65, 203-209 (2005).
57. Lee, S. et al. Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8, 155-167 (2005).
58. Kim, J. W. & Dang, C. V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 30, 142-150 (2005).
59. Majewski, N. et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16, 819-830 (2004).
60. Storz, P. Reactive oxygen species in tumor progression. Front. Biosci. 10, 1881-1896 (2005).
61. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (Suppl.), 62-67 (2002).
62. Covello, K. L. & Simon, M. C. HIFs, hypoxia, and vascular development. Curr. Top. Dev. Biol. 62, 37-54 (2004).
63. Yeo, H. & Roman, S. Pheochromocytoma and functional paraganglioma. Curr. Opin. Oncol. 17, 13-18 (2005).
64. Lopez-Barneo, J., del Toro, R., Levitsky, K. L., Chiara, M. D. & Ortega-Saenz, P. Regulation of oxygen sensing by ion channels. J. Appl. Physiol. 96, 1187-1195 (2004).
65. Astrom, K., Cohen, J. E., Willett-Brozick, J. E., Aston, C. E. & Baysal, B. E. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum. Genet. 113, 228-237 (2003). Shows that low oxygen-tension (high altitude) increases the penetrance and the severity of tumours with SDHD mutations. This is an independent confirmation of the phenotypic link between SDH dysfunction and pseudo-hypoxia.
66. Baysal, B. E. Genomic imprinting and environment in hereditary paraganglioma. Am. J. Med. Genet. C. Semin. Med. Genet. 129, 85-90 (2004).
67. Gimenez-Roqueplo, A. P. et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzy z-Roqueplo, A. P. et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab. 87, 4771-4774 (2002).
68. Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005).
69. Dahia, P. L. M. et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1, e8 (2005).
70. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
71. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
72. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019-1027 (2001).
73. Clifford, S. C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029-1038 (2001).
74. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer 2, 38-47 (2002).
75. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
76. Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899 (2004).
77. Sowter, H. M., Ratcliffe, P. J., Watson, P., Greenberg, A. H. & Harris, A. L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61, 6669-6673 (2001).
78. Erler, J. T. et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24, 2875-2889 (2004).
79. Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146 (2003).
80. Safran, M. & Kaelin, W. G. Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111, 779-783 (2003).
81. Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nature Rev. Mol. Cell Biol. 5, 343-354 (2004).
82. 2 sensing. J. Biol. Chem. 275, 25130-25138 (2000).
83. Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (2004).
84. Gerald, D. et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794 (2004). Gives biochemical evidence that ROS (hydrogen peroxide) can inhibit HIF PHD activity.
85. Dalgard, C. L., Lu, H., Mohyeldin, A. & Verma, A. Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem. J. 380, 419-424 (2004).
86. Colombini, M., Blachly-Dyson, E. & Forte, M. VDAC, a channel in the outer mitochondrial membrane. Ion Channels 4, 169-202 (1996).
87. Palmieri, F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch. 447, 689-709 (2004).
88. Butow, R. A. & Avadhani, N. G. Mitochondrial signaling: the retrograde response. Mol. Cell 14, 1-15 (2004).
89. Marx, J. Cell biology. How cells endure low oxygen. Science 303, 1454-1456 (2004).
90. Kaelin, W. G. Jr. ROS: really involved in oxygen sensing. Cell. Metab. 1, 357-358 (2005).
91. Hutton, J. J. Jr, Tappel, A. L. & Udenfriend, S. Cofactor and substrate requirements of collagen proline hydroxylase. Arch. Biochem. Biophys. 118, 231-240 (1967).
92. Myllyla, R., Tuderman, L. & Kivirikko, K. I. Mechanism of the prolyl hydroxylase reaction. 2. Kinetic analysis of the reaction sequence. Eur. J. Biochem. 80, 349-357 (1977).
93. Badenhop, R. F. et al. Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer 31, 255-263 (2001).
94. van Schothorst, E. M. et al. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Hum. Pathol. 29, 1045-1049 (1998).
95. Hensen, E. F. et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23, 4076-4083 (2004).
96. Raha, S. & Robinson, B. H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25, 502-508 (2000).
97. Messner, K. R. & Imlay, J. A. Mechanism of superoxide and hydrogen peroxide formation by fumarate reductase, succinate dehydrogenase, and aspartate oxidase. J. Biol. Chem. 277, 42563-42571 (2002).
98. Paddenberg, R. et al. Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L710-L719 (2003).